Literature DB >> 34208232

Inhibition of the Human Hsc70 System by Small Ligands as a Potential Anticancer Approach.

Leire Dublang1,2, Jarl Underhaug3,4, Marte I Flydal3, Lorea Velasco-Carneros1,2, Jean-Didier Maréchal5, Fernando Moro1,2, Maria Dolores Boyano6,7, Aurora Martinez3, Arturo Muga1,2.   

Abstract

Heat shock protein (Hsp) synthesis is upregulated in a wide range of cancers to provide the appropriate environment for tumor progression. The Hsp110 and Hsp70 families have been associated to cancer cell survival and resistance to chemotherapy. In this study, we explore the strategy of drug repurposing to find new Hsp70 and Hsp110 inhibitors that display toxicity against melanoma cancer cells. We found that the hits discovered using Apg2, a human representative of the Hsp110 family, as the initial target bind also to structural regions present in members of the Hsp70 family, and therefore inhibit the remodeling activity of the Hsp70 system. One of these compounds, the spasmolytic agent pinaverium bromide used for functional gastrointestinal disorders, inhibits the intracellular chaperone activity of the Hsp70 system and elicits its cytotoxic activity specifically in two melanoma cell lines by activating apoptosis. Docking and molecular dynamics simulations indicate that this compound interacts with regions located in the nucleotide-binding domain and the linker of the chaperones, modulating their ATPase activity. Thus, repurposing of pinaverium bromide for cancer treatment appears as a promising novel therapeutic approach.

Entities:  

Keywords:  chaperones; drug repurposing; inhibitors; melanoma; pinaverium bromide

Year:  2021        PMID: 34208232     DOI: 10.3390/cancers13122936

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  1 in total

1.  Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop.

Authors:  Junjie Gu; Yuanyuan Sun; Jiahang Song; Ruiling Zhao; Xiaoke Di; Yumeng Zhang; Xiaolin Ge; Shu Zhang; Yun Gu; Xinchen Sun
Journal:  J Exp Clin Cancer Res       Date:  2022-08-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.